Publication:
Spread of artemisinin resistance in Plasmodium falciparum malaria

dc.contributor.authorE. A. Ashleyen_US
dc.contributor.authorM. Dhordaen_US
dc.contributor.authorR. M. Fairhursten_US
dc.contributor.authorC. Amaratungaen_US
dc.contributor.authorP. Limen_US
dc.contributor.authorS. Suonen_US
dc.contributor.authorS. Srengen_US
dc.contributor.authorJ. M. Andersonen_US
dc.contributor.authorS. Maoen_US
dc.contributor.authorB. Samen_US
dc.contributor.authorC. Sophaen_US
dc.contributor.authorC. M. Chuoren_US
dc.contributor.authorC. Nguonen_US
dc.contributor.authorS. Sovannarothen_US
dc.contributor.authorS. Pukrittayakameeen_US
dc.contributor.authorP. Jittamalaen_US
dc.contributor.authorK. Chotivanichen_US
dc.contributor.authorK. Chutasmiten_US
dc.contributor.authorC. Suchatsoonthornen_US
dc.contributor.authorR. Runcharoenen_US
dc.contributor.authorT. T. Hienen_US
dc.contributor.authorN. T. Thuy-Nhienen_US
dc.contributor.authorN. V. Thanhen_US
dc.contributor.authorN. H. Phuen_US
dc.contributor.authorY. Htuten_US
dc.contributor.authorK. T. Hanen_US
dc.contributor.authorK. H. Ayeen_US
dc.contributor.authorO. A. Mokuoluen_US
dc.contributor.authorR. R. Olaosebikanen_US
dc.contributor.authorO. O. Folaranmien_US
dc.contributor.authorM. Mayxayen_US
dc.contributor.authorM. Khanthavongen_US
dc.contributor.authorB. Hongvanthongen_US
dc.contributor.authorP. N. Newtonen_US
dc.contributor.authorM. A. Onyambokoen_US
dc.contributor.authorC. I. Fanelloen_US
dc.contributor.authorA. K. Tshefuen_US
dc.contributor.authorN. Mishraen_US
dc.contributor.authorN. Valechaen_US
dc.contributor.authorA. P. Phyoen_US
dc.contributor.authorF. Nostenen_US
dc.contributor.authorP. Yien_US
dc.contributor.authorR. Tripuraen_US
dc.contributor.authorS. Borrmannen_US
dc.contributor.authorM. Bashraheilen_US
dc.contributor.authorJ. Peshuen_US
dc.contributor.authorM. A. Faizen_US
dc.contributor.authorA. Ghoseen_US
dc.contributor.authorM. A. Hossainen_US
dc.contributor.authorR. Samaden_US
dc.contributor.authorM. R. Rahmanen_US
dc.contributor.authorM. M. Hasanen_US
dc.contributor.authorA. Islamen_US
dc.contributor.authorO. Miottoen_US
dc.contributor.authorR. Amatoen_US
dc.contributor.authorB. MacInnisen_US
dc.contributor.authorJ. Stalkeren_US
dc.contributor.authorD. P. Kwiatkowskien_US
dc.contributor.authorZ. Bozdechen_US
dc.contributor.authorA. Jeeyapanten_US
dc.contributor.authorP. Y. Cheahen_US
dc.contributor.authorT. Sakulthaewen_US
dc.contributor.authorJ. Chalken_US
dc.contributor.authorB. Intharabuten_US
dc.contributor.authorK. Silamuten_US
dc.contributor.authorS. J. Leeen_US
dc.contributor.authorB. Vihokhernen_US
dc.contributor.authorC. Kunasolen_US
dc.contributor.authorM. Imwongen_US
dc.contributor.authorJ. Tarningen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherPhusing Hospitalen_US
dc.contributor.otherKhunhan Hospitalen_US
dc.contributor.otherKraburi Hospitalen_US
dc.contributor.otherUniversity of Oxforden_US
dc.contributor.otherNuffield Department of Clinical Medicineen_US
dc.contributor.otherWellcome Trust Centre for Human Geneticsen_US
dc.contributor.otherWellcome Trust Sanger Instituteen_US
dc.contributor.otherLondon School of Hygiene & Tropical Medicineen_US
dc.contributor.otherUniversity of Maryland, Baltimoreen_US
dc.contributor.otherNational Institute of Allergy and Infectious Diseasesen_US
dc.contributor.otherNational Center for Parasitology, Entomology and Malaria Controlen_US
dc.contributor.otherSampov Meas Referral Hospitalen_US
dc.contributor.otherRatanakiri Referral Hospitalen_US
dc.contributor.otherMakara 16 Referral Hospitalen_US
dc.contributor.otherUCLen_US
dc.contributor.otherDepartment of Medical Researchen_US
dc.contributor.otherUniversity of Ilorinen_US
dc.contributor.otherMahosot Hospitalen_US
dc.contributor.otherUniversity of Health Sciencesen_US
dc.contributor.otherCentre of Malariologyen_US
dc.contributor.otherKinshasa School of Public Healthen_US
dc.contributor.otherNational Institute of Malaria Research Indiaen_US
dc.contributor.otherWellcome Trust Research Laboratories Nairobien_US
dc.contributor.otherUniversitat Tubingenen_US
dc.contributor.otherMalaria Research Group and Dev Care Foundationen_US
dc.contributor.otherShaheed Suhrawardy Medical Collegeen_US
dc.contributor.otherChittagong Medical Collegeen_US
dc.contributor.otherRamu Upazila Health Complexen_US
dc.contributor.otherNanyang Technological Universityen_US
dc.date.accessioned2018-11-09T03:06:57Z
dc.date.available2018-11-09T03:06:57Z
dc.date.issued2014-01-01en_US
dc.description.abstractBACKGROUND: Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia and now poses a threat to the control and elimination of malaria. Mapping the geographic extent of resistance is essential for planning containment and elimination strategies. METHODS: Between May 2011 and April 2013, we enrolled 1241 adults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15 sites in 10 countries (7 in Asia and 3 in Africa). Patients received artesunate, administered orally at a daily dose of either 2 mg per kilogram of body weight per day or 4 mg per kilogram, for 3 days, followed by a standard 3-day course of artemisinin-based combination therapy. Parasite counts in peripheral-blood samples were measured every 6 hours, and the parasite clearance half-lives were determined. RESULTS: The median parasite clearance half-lives ranged from 1.9 hours in the Democratic Republic of Congo to 7.0 hours at the Thailand-Cambodia border. Slowly clearing infections (parasite clearance half-life >5 hours), strongly associated with single point mutations in the "propeller" region of the P. falciparum kelch protein gene on chromosome 13 (kelch13), were detected throughout mainland Southeast Asia from southern Vietnam to central Myanmar. The incidence of pretreatment and post-treatment gametocytemia was higher among patients with slow parasite clearance, suggesting greater potential for transmission. In western Cambodia, where artemisinin-based combination therapies are failing, the 6-day course of antimalarial therapy was associated with a cure rate of 97.7% (95% confidence interval, 90.9 to 99.4) at 42 days. CONCLUSIONS: Artemisinin resistance to P. falciparum, which is now prevalent across mainland Southeast Asia, is associated with mutations in kelch13. Prolonged courses of artemisinin-based combination therapies are currently efficacious in areas where standard 3-day treatments are failing. Copyright © 2014 Massachusetts Medical Society.en_US
dc.identifier.citationNew England Journal of Medicine. Vol.371, No.5 (2014), 411-423en_US
dc.identifier.doi10.1056/NEJMoa1314981en_US
dc.identifier.issn15334406en_US
dc.identifier.issn00284793en_US
dc.identifier.other2-s2.0-84904892931en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/34882
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84904892931&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleSpread of artemisinin resistance in Plasmodium falciparum malariaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84904892931&origin=inwarden_US

Files

Collections